OTCMKTS:IPSEY Ipsen (IPSEY) Stock Price, News & Analysis $28.33 0.00 (0.00%) As of 02/21/2025 03:19 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest About Ipsen Stock (OTCMKTS:IPSEY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ipsen alerts:Sign Up Key Stats Today's Range$28.33▼$28.3350-Day Range$27.28▼$32.0452-Week Range$27.09▼$34.06Volume386 shsAverage Volume615 shsMarket Capitalization$9.50 billionP/E RatioN/ADividend Yield0.74%Price TargetN/AConsensus RatingN/A Company OverviewIpsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.Read More… Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Stock News HeadlinesBarclays Reaffirms Their Hold Rating on Ipsen (0MH6)February 18, 2025 | markets.businessinsider.comUBS Sticks to Their Buy Rating for Ipsen (0MH6)February 14, 2025 | markets.businessinsider.com70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.February 23, 2025 | WealthPress (Ad)Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...February 14, 2025 | finance.yahoo.comIpsen targets 5%+ sales growth and 30%+ margin for 2025 amid strong pipeline and launchesFebruary 13, 2025 | msn.comIpsen S.A. (IPSEY) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comIpsen stock falls following mixed Q4 resultsFebruary 13, 2025 | msn.comIpsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025February 13, 2025 | markets.businessinsider.comSee More Headlines IPSEY Stock Analysis - Frequently Asked Questions How have IPSEY shares performed this year? Ipsen's stock was trading at $28.97 at the beginning of 2025. Since then, IPSEY stock has decreased by 2.2% and is now trading at $28.33. View the best growth stocks for 2025 here. How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today2/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,325Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.14 Quick Ratio0.98 Sales & Book Value Annual Sales$3.87 billion Price / Sales2.46 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares335,260,000Free FloatN/AMarket Cap$9.50 billion OptionableNot Optionable Beta0.92 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:IPSEY) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ipsen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.